E-selectin expression and BRAF status in papillary thyroid carcinomas: Correlation with clinicopathologic features.

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Cell adhesion molecules, including selectins, are implicated in cancer progression.
• Previous studies suggest a link between selectins and tumor aggressiveness.

Purpose of the Study:

• To investigate the role of E-selectin expression in papillary thyroid carcinoma (PTC).
• To determine the correlation between E-selectin expression, tumor characteristics, and BRAF mutation status in PTC.

Main Methods:

• Eighty-eight PTC patients were analyzed, categorized by encapsulated tumors versus extrathyroidal extension.
• E-selectin expression was quantified using immunohistochemical staining and RT-PCR, with results normalized via z-scores.
• Correlation analysis was performed with clinicopathological features and BRAF mutation status.

Main Results:

• Extrathyroidal extension was associated with significantly higher rates of lymph node metastasis (40.4% vs 4.8%) and BRAF mutations (65.9% vs 51.2%).
• Mean E-selectin z-scores were higher in tumors with extrathyroidal extension (0.28) compared to encapsulated tumors (-0.32).
• E-selectin expression positively correlated with neoplastic infiltration, AJCC stage, and BRAF mutation.

Conclusions:

• E-selectin overexpression is associated with a more aggressive phenotype in papillary thyroid carcinoma.
• The combination of E-selectin overexpression and BRAF mutation may drive tumor aggressiveness.
• E-selectin may serve as a potential biomarker for predicting aggressive PTC behavior.